Randomized Feasibility Study of Discontinuation versus Continuation of Immunosuppressive Therapy (IST) in Patients with Chronic Graft Versus Host Disease (GVHD)
Prior first allogeneic stem cell transplant, with any graft source, donor type, and GVHD prophylaxis
Patients who are on one systemic immunosuppressive agent for chronic GVHD with a plan to withdraw all systemic IST; hydrocortisone continued for treatment of adrenal insufficiency is not considered a systemic IST
No evidence of malignancy at the time of enrollment
Agree to be evaluated at the transplant center or by local provider every 3 months for 12 months after randomization
Agreement to be contacted by phone or e-mail for health status evaluation for up to 3 years
Signed, informed consent
Other eligibility criteria may apply.
Inability to comply with study procedures
Other exclusion criteria may apply.